INTRODUCTION: Vitamin D receptor activator (VDRA) therapy has been shown to be associated with reduced mortality rates in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT). However, differences between VDRAs in their ability to reduce both all-cause and cardiovascular-related mortality rates are not yet fully elucidated. METHODS: The objective of the current analysis was to determine the effect of VDRA therapy on mortality in an Italian dialysis population, observed prospectively every 6 months for 18 months. Patients were investigated for all-cause and cardiovascular-related mortality risk adjusted for various demographic, clinical, and/or SHPT treatment variables. RESULTS: The cumulative probabilities of all-cause and cardiovascular-related mortality were lower for patients who received any VDRA treatment compared with those who did not (p < 0.001) regardless of all measured variables. Additionally, patients who received paricalcitol and/or cinacalcet (with or without VDRAs) compared with calcitriol showed a significant improvement in both all-cause and cardiovascular-related mortality (p < 0.001). Cinacalcet with or without VDRAs was not associated with a further decrease of mortality hazard ratios compared with paricalcitol monotherapy. CONCLUSIONS: VDRA therapy (associated or not with cinacalcet) was associated with improved survival in dialysis patients, independent of demographic and clinical variables.
INTRODUCTION: Vitamin D receptor activator (VDRA) therapy has been shown to be associated with reduced mortality rates in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT). However, differences between VDRAs in their ability to reduce both all-cause and cardiovascular-related mortality rates are not yet fully elucidated. METHODS: The objective of the current analysis was to determine the effect of VDRA therapy on mortality in an Italian dialysis population, observed prospectively every 6 months for 18 months. Patients were investigated for all-cause and cardiovascular-related mortality risk adjusted for various demographic, clinical, and/or SHPT treatment variables. RESULTS: The cumulative probabilities of all-cause and cardiovascular-related mortality were lower for patients who received any VDRA treatment compared with those who did not (p < 0.001) regardless of all measured variables. Additionally, patients who received paricalcitol and/or cinacalcet (with or without VDRAs) compared with calcitriol showed a significant improvement in both all-cause and cardiovascular-related mortality (p < 0.001). Cinacalcet with or without VDRAs was not associated with a further decrease of mortality hazard ratios compared with paricalcitol monotherapy. CONCLUSIONS: VDRA therapy (associated or not with cinacalcet) was associated with improved survival in dialysis patients, independent of demographic and clinical variables.
Authors: Akshay Varghese; Eduardo Lacson; Jessica M Sontrop; Rey R Acedillo; Ahmed A Al-Jaishi; Sierra Anderson; Amit Bagga; Katie L Bain; Laura L Bennett; Clara Bohm; Pierre A Brown; Christopher T Chan; Brenden Cote; Varun Dev; Bonnie Field; Claire Harris; Shasikara Kalatharan; Mercedeh Kiaii; Amber O Molnar; Matthew J Oliver; Malvinder S Parmar; Melissa Schorr; Nikhil Shah; Samuel A Silver; D Michael Smith; Manish M Sood; Irina St Louis; Karthik K Tennankore; Stephanie Thompson; Marcello Tonelli; Hans Vorster; Blair Waldvogel; James Zacharias; Amit X Garg Journal: Can J Kidney Health Dis Date: 2020-10-22
Authors: Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino Journal: J Nephrol Date: 2016-04-09 Impact factor: 3.902
Authors: Andrea Galassi; Antonio Bellasi; Sara Auricchio; Sergio Papagni; Mario Cozzolino Journal: Biomed Res Int Date: 2013-08-07 Impact factor: 3.411
Authors: Nicholas J A Webb; Gary Lerner; Bradley A Warady; Katherine M Dell; Larry A Greenbaum; Gema Ariceta; Bernd Hoppe; Peter Linde; Ho-Jin Lee; Ann Eldred; Matthew B Dufek Journal: Pediatr Nephrol Date: 2017-03-22 Impact factor: 3.714